Delays in cervical cancer treatment initiation for patients living with or without HIV in Botswana: An observational cohort analysis (2015-2019).

HIV cervical cancer chemoradiation delays in treatment initiation radiation

Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
08 Mar 2024
Historique:
received: 27 09 2023
revised: 04 02 2024
accepted: 18 02 2024
medline: 11 3 2024
pubmed: 11 3 2024
entrez: 10 3 2024
Statut: aheadofprint

Résumé

Present delays in treatment initiation of chemoradiation or radiation alone for patients with advanced stage cervical cancer in Botswana. Women with locally advanced cervical cancer (stages IB2-IVB) were prospectively enrolled in an observational cohort study in 2015-2019. We evaluated delays at 30, 60, 90, 120, 150, and 180 or greater days between the date of diagnosis and treatment initiation. Factors associated with overall survival (OS) were modeled with multivariable Cox proportional hazards regression (aHR). Associations between delays in cervical cancer treatment initiation were evaluated via univariable logistic regression. Among the 556 patients included (median age = 47.9 years), 386 (69.4%) were women living with HIV with a median CD4 count of 448.0 cells/μL (IQR, 283.0-647.5 cells/μL) at diagnosis. Most patients had stages II (38.1%) and III (34.5%) cervical cancer. Early-stage patients experienced longer delays in treatment initiation compared to late-stage patients (p=0.033). Early-stage patients with delays ≥90 days and pathology diagnosis between 2016-2019 (aHR 0.34, p<0.001) versus <90 days decreased the risk of mortality, while those with delays ≥90 days and pathology diagnosis before 2016 (aHR 5.67, p=0.022) versus <90 days increased the risk the mortality. Late-stage patients with delays ≥120 days and pathology diagnosis between 2018-2019 (aHR 1.98, p=0.025) versus <120 days increased the risk the mortality. Early-stage patients with pathology diagnosis between 2016-2019 (OR 2.32, p=0.043) versus before 2016 were more likely to experience delays ≥90 days and late-stage patients who traveled >100 km to the treatment facility (OR 2.83, p<0.001) versus <100 km were more likely to experience delays ≥120 days. Delays in care are common in Botswana, particularly for those living farther from the treatment clinic and at advanced stages. This paper is among the first to show an association between treatment delays and worsened OS at advanced stages of cervical cancer, highlighting the need for interventions to help patients receive timely care in global settings.

Identifiants

pubmed: 38462016
pii: S0360-3016(24)00354-7
doi: 10.1016/j.ijrobp.2024.02.038
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Jessica George (J)

Donald Bren School of Information and Computer Sciences, University of California, Irvine, Irvine, CA.

Shawna Tuli (S)

Donald Bren School of Information and Computer Sciences, University of California, Irvine, Irvine, CA.

Palak P Patel (PP)

Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Barati Monare (B)

Botswana-University of Pennsylvania Partnership, Gaborone, Botswana.

Doreen Ramogola-Masire (D)

Department of Obstetrics & Gynecology, University of Botswana, Gaborone, Botswana.

Lisa Bazzett-Matabele (L)

Department of Obstetrics & Gynecology, University of Botswana, Gaborone, Botswana; Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT.

Memory Bvochora-Nsingo (M)

Department of Oncology, Gaborone Private Hospital, Gaborone, Botswana.

Sebathu Chiyapo (S)

Princess Marina Hospital, Gaborone, Botswana.

Tlotlo Ralefala (T)

Princess Marina Hospital, Gaborone, Botswana.

Peter Vuylsteke (P)

CHU Namur, Site Sainte-Elisabeth, UCLouvain, Namur, Belgium; Department of Internal Medicine, University of Botswana, Gaborone, Botswana.

Katharine A Rendle (KA)

Department of Family Medicine & Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.

Surbhi Grover (S)

Botswana-University of Pennsylvania Partnership, Gaborone, Botswana; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. Electronic address: surbhi.grover@pennmedicine.upenn.edu.

Classifications MeSH